Céline Louapre
Céline Louapre
ICM, Pitie-Salpetriere Hospital, Paris, France
Bestätigte E-Mail-Adresse bei aphp.fr
TitelZitiert vonJahr
Brain networks disconnection in early multiple sclerosis cognitive deficits: an anatomofunctional study
C Louapre, V Perlbarg, D García‐Lorenzo, M Urbanski, H Benali, ...
Human brain mapping 35 (9), 4706-4717, 2014
Neuroinflammatory component of gray matter pathology in multiple sclerosis
E Herranz, C Giannì, C Louapre, CA Treaba, ST Govindarajan, ...
Annals of neurology 80 (5), 776-790, 2016
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging
C Mainero, C Louapre, ST Govindarajan, C Giannì, AS Nielsen, ...
Brain 138 (4), 932-945, 2015
Dynamic I maging of I ndividual R emyelination P rofiles in M ultiple S clerosis
B Bodini, M Veronese, D García‐Lorenzo, M Battaglini, E Poirion, ...
Annals of neurology 79 (5), 726-738, 2016
Stimulation of CDP-choline synthesis by uridine or cytidine in PC12 rat pheochromocytoma cells
UI Richardson, CJ Watkins, C Pierre, IH Ulus, RJ Wurtman
Brain research 971 (2), 161-167, 2003
Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance
L Grimaldi-Bensouda, M Rossignol, I Koné-Paut, A Krivitzky, ...
Journal of autoimmunity 79, 84-90, 2017
In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis
T Granberg, Q Fan, CA Treaba, R Ouellette, E Herranz, G Mangeat, ...
Brain 140 (11), 2912-2926, 2017
Beyond focal cortical lesions in MS: an in vivo quantitative and spatial imaging study at 7T
C Louapre, ST Govindarajan, C Giannì, C Langkammer, JA Sloane, ...
Neurology 85 (19), 1702-1709, 2015
Reproducibility of T2* mapping in the human cerebral cortex in vivo at 7 tesla MRI
ST Govindarajan, J Cohen‐Adad, MP Sormani, AP Fan, C Louapre, ...
Journal of Magnetic Resonance Imaging 42 (2), 290-296, 2015
Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy
H Hendel-Chavez, MGG de Herve, C Giannesini, AA Mazet, C Papeix, ...
Journal of virology 87 (10), 6055-6059, 2013
Neurodegeneration in multiple sclerosis is a process separate from inflammation: Yes
C Louapre, C Lubetzki
Multiple Sclerosis Journal 21 (13), 1626-1628, 2015
The neuronal component of gray matter damage in multiple sclerosis: A [11C]flumazenil positron emission tomography study
L Freeman, D Garcia‐Lorenzo, L Bottin, C Leroy, C Louapre, B Bodini, ...
Annals of neurology 78 (4), 554-567, 2015
Advanced imaging tools to investigate multiple sclerosis pathology
B Bodini, C Louapre, B Stankoff
La Presse Médicale 44 (4), e159-e167, 2015
Clinical and MRI characterization of MS patients with a pure and severe cognitive onset
R Assouad, C Louapre, A Tourbah, C Papeix, D Galanaud, C Lubetzki, ...
Clinical neurology and neurosurgery 126, 55-63, 2014
The association between intra-and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T2* mapping at 7 T MRI
C Louapre, ST Govindarajan, C Giannì, N Madigan, AS Nielsen, ...
NeuroImage: Clinical 12, 879-886, 2016
Natalizumab-PML survivors with subsequent MS treatment: clinico-radiologic outcome
E Maillart, JS Vidal, D Brassat, B Stankoff, A Fromont, J de Sèze, F Taithe, ...
Neurology-Neuroimmunology Neuroinflammation 4 (3), e346, 2017
Imaging markers of multiple sclerosis prognosis
C Louapre, B Bodini, C Lubetzki, L Freeman, B Stankoff
Current opinion in neurology 30 (3), 231-236, 2017
Meningeal inflammation in multiple sclerosis: The key to the origin of cortical lesions?
C Mainero, C Louapre
Neurology 85 (1), 12-13, 2015
Migraine and Inhibitory System–I Can't Hold It!
C Mainero, C Louapre
Current pain and headache reports 18 (7), 426, 2014
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
E Maillart, C Louapre, C Lubetzki, C Papeix
Multiple Sclerosis Journal 20 (4), 505-509, 2014
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20